Category: Replacement Heart Valves
On-X Life Technologies says it's launching a mitral valve chordal repair system, dubbed Chord-X.
On-X Life Technologies said it's launching Chord-X, a new mitral valve chordal repair system using the company's proprietary sutures.
Replacement heart valves once again take center stage at the annual EuroPCR conference in Paris this week, as Edwards Lifesciences pauses its Fortis trial and positive new data comes in on the next generation of aortic implants.
Direct Flow Medical says 2-year data from its Discover CE Mark trial showed an 80% survival rate at 2 years for its transcatheter aortic valve implant.
Direct Flow Medical today said data from a clinical trial of its replacement heart valve showed an 80% survival rate after 2 years.
Edwards Lifesciences halts enrollment in a clinical trial of its Fortis mitral valve implant after some patients developed blood clots in the devices.
Delays in Neovasc’s early feasibility trial for its Tiara transcatheter mitral valve implant and declining 1st-quarter profits push its stock price down.
Delays in Neovasc's (NSDQ:NVCN) early feasibility trial for its Tiara transcatheter mitral valve implant and declining 1st-quarter profits combined to push its stock price down this week.
Abbot’s MitraClip cut ventricular tachyarrhythmias by 50% in patients with mitral regurgitation and a rhythm management device.
Biotronik touts 1st-in-human data for its entry into the transcatheter aortic valve implant market, saying the device passed its 30-day safety endpoint.
Biotronik today said its entry into a hot replacement heart valve market passed the safety endpoint of a 1st-in-human trial.
The German medical device giant said the Biovalve trial of its transcatheter aortic valve implant established the device's early safety at 30 days.